COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01540604
Recruitment Status : Completed
First Posted : February 29, 2012
Last Update Posted : October 2, 2012
Information provided by (Responsible Party):
RSPR Pharma AB

Brief Summary:
This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.

Condition or disease Intervention/treatment Phase
Duchenne Muscular Dystrophy Becker Muscular Dystrophy Drug: CRD007 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Official Title: An Open-label, Un-controlled, Single-centre Trial Investigating the Efficacy and Safety of CRD007 in Children With Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD) or Children Being Symptomatic Carriers for DMD or BMD

Arm Intervention/treatment
Experimental: CRD007 10 mg tablet Drug: CRD007

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 11 Years   (Child)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Documented diagnosis of dystrophinopathy

Exclusion Criteria:

  • Severe functional impairment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01540604

Layout table for location information
Stockholm, Sweden
Sponsors and Collaborators
RSPR Pharma AB
Layout table for investigator information
Principal Investigator: T Sejersen, MD PhD Karolinska University Hospital

Layout table for additonal information
Responsible Party: RSPR Pharma AB Identifier: NCT01540604    
Other Study ID Numbers: Cardoz-004
First Posted: February 29, 2012    Key Record Dates
Last Update Posted: October 2, 2012
Last Verified: October 2012
Keywords provided by RSPR Pharma AB:
symptomatic carriers
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked